14,900 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Aristides Capital LLC

Aristides Capital LLC bought a new stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 4th quarter, HoldingsChannel reports. The firm bought 14,900 shares of the company’s stock, valued at approximately $197,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of SNDX. Russell Investments Group Ltd. raised its position in shares of Syndax Pharmaceuticals by 114.8% during the 4th quarter. Russell Investments Group Ltd. now owns 29,022 shares of the company’s stock valued at $384,000 after buying an additional 15,508 shares in the last quarter. Wells Fargo & Company MN increased its stake in Syndax Pharmaceuticals by 37.6% in the fourth quarter. Wells Fargo & Company MN now owns 42,117 shares of the company’s stock valued at $557,000 after acquiring an additional 11,498 shares during the last quarter. Bryce Point Capital LLC purchased a new stake in Syndax Pharmaceuticals during the fourth quarter valued at about $417,000. Knott David M Jr lifted its stake in Syndax Pharmaceuticals by 4.8% during the fourth quarter. Knott David M Jr now owns 128,000 shares of the company’s stock worth $1,692,000 after purchasing an additional 5,856 shares during the last quarter. Finally, Trexquant Investment LP boosted its holdings in shares of Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company’s stock worth $6,230,000 after purchasing an additional 437,859 shares in the last quarter.

Insider Transactions at Syndax Pharmaceuticals

In other news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the transaction, the chief financial officer now owns 90,746 shares of the company’s stock, valued at $1,406,563. The trade was a 4.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Neil Gallagher sold 4,618 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. This represents a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 21,683 shares of company stock valued at $336,087. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on SNDX. JPMorgan Chase & Co. raised their price objective on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, March 20th. HC Wainwright reissued a “buy” rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank cut their price objective on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a research report on Wednesday, April 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $36.20.

Syndax Pharmaceuticals Trading Down 2.1 %

Syndax Pharmaceuticals stock opened at $11.01 on Tuesday. The firm has a market cap of $947.34 million, a P/E ratio of -3.03 and a beta of 1.28. Syndax Pharmaceuticals, Inc. has a 1-year low of $10.14 and a 1-year high of $25.07. The firm has a 50-day moving average of $14.06 and a 200-day moving average of $15.60.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.32 million. Research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).